Mrs Vijayakala Mani, PA-C | |
2895 Lewis Ln, Paris, TX 75460-9331 | |
(972) 203-3600 | |
(972) 203-3601 |
Full Name | Mrs Vijayakala Mani |
---|---|
Gender | Female |
Speciality | Pain Medicine - Pain Medicine |
Location | 2895 Lewis Ln, Paris, Texas |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295988640 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Mrs Vijayakala Mani, PA-C Po Box 1200, Colleyville, TX 76034-1200 Ph: (972) 203-3600 | Mrs Vijayakala Mani, PA-C 2895 Lewis Ln, Paris, TX 75460-9331 Ph: (972) 203-3600 |
News Archive
In recent years, many groups, including policy makers and health systems, have looked for ways to reduce the number of visits to the emergency department (ED) as a way to lower costs and improve the quality of care. Research conducted by Jesse Pines, M.D., director of the Office of Clinical Practice Innovation and professor of emergency medicine at the George Washington University (GW) School of Medicine and Health Sciences, explored interventions that had been implemented outside of EDs that were designed to reduce ED use.
Amble, stroll or pedal: it's all good. A new study provides evidence supporting a seemingly obvious − but unproven − link between walking- and cycling-friendly communities and lower levels of obesity.
Scientists are adding additional brush strokes to the revolutionary new image now emerging for star-shaped cells called astrocytes in the brain and spinal cord. Their report, which suggests a key role for astrocytes in morphine's ability to relieve pain and cause addiction, appears online in ACS' Journal of Proteome Research, a monthly publication.
n an in-depth study of how COVID-19 affects a patient's brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease.
CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC's human cell line, CAP-Technology, with Catalent's unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.
› Verified 5 days ago
Kimberly Smith, MSN, APRN, FNP-BC Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2895 Lewis Ln, Paris, TX 75460 Phone: 972-203-3600 |